US FDA declines to approve higher-dose of Biogen's genetic disorder drug
23/09/2025 21:35
Sept 23 (Reuters) - The U.S. Food and Drug Administration has declined to approve a higher dose version of Biogen's BIIB.O drug for a rare genetic disorder that causes progressive muscle weakness, dealing a setback to the company's efforts to strengthen its position in a competitive market, the company said on Tuesday. (Reporting by Kamal Choudhury, Mariam Sunny and Siddhi Mahatole in Bengaluru; Editing by Krishna Chandra Eluri) ((Kamal.Choudhury@thomsonreuters.com;))
Recent news on Ionis Pharmaceuticals
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: Ionis Announces License Agreement With Recordati For Zilganersen In Alexander Disease (Axd) In All Countries Outside The U.S.
Brief: Ionis Pharmaceuticals Says FDA Approved Tryngolza For Severe Hypertriglyceridemia
Brief: FDA Approves Treatment To Reduce Risk Of Acute Pancreatitis In Adults With Severe Hypertriglyceridemia
Brief: Ionis Announces Appointment Of Ludwig Hantson, Ph.D. To Board Of Directors